Ozempic babies: separating real risk from TikTok panic

What did @brownricebandit actually say?

The creator made two distinct claims about why people on semaglutide might experience unexpected pregnancies. First, that Ozempic is "a GLP-1 antagonist" that delays gastric emptying and reduces oral birth control absorption. Second, that people who were infertile due to obesity are regaining fertility after significant weight loss on the drug. The video frames both as real, documented phenomena worth knowing about. Credit where it's due: the general premise is not invented. There are legitimate clinical conversations happening about both of these mechanisms. The problem is the creator garbles some of the science badly enough to mislead viewers about the actual risks.

Does the science back this up?

Partially, but with important corrections. The FDA issued a drug interaction warning in 2023 specifically noting that semaglutide's gastric emptying delay could reduce absorption of oral medications, including contraceptives. A 2023 pharmacokinetic study (Semaglutide labels, FDA drug interaction data) confirmed that peak concentration of oral contraceptives containing levonorgestrel and ethinyl estradiol was reduced when taken with semaglutide. On the fertility side, the connection between obesity-related conditions like polycystic ovary syndrome (PCOS) and anovulation is well-established. Weight loss, whether from GLP-1 medications or lifestyle change, can restore ovulatory function in women with obesity-related infertility. A 2023 case series published in the Journal of the Endocrine Society documented pregnancies in women with PCOS who had previously struggled to conceive, following semaglutide use.

What did they get wrong (or right)?

Here is the biggest error: semaglutide is a GLP-1 agonist, not an antagonist. The creator says "it's a GLP-1 antagonist" which is the opposite of what it actually is. An antagonist blocks a receptor. Semaglutide works by activating GLP-1 receptors, which is what produces the gastric emptying delay and insulin response in the first place. This is not a small verbal slip. Understanding agonist versus antagonist is foundational pharmacology, and getting it wrong undermines the explanation the creator is trying to give.

What they got right: the gastric emptying mechanism is real, the birth control absorption concern is real, and the obesity-related fertility restoration angle is real and underreported. The advice to use backup contraception or switch to non-oral methods while on GLP-1 medications is consistent with current clinical guidance. The framing that this applies to weight loss from diet and exercise too, not just Ozempic, is also correct and worth noting.

• Wrong: GLP-1 antagonist (should be agonist)
• Right: gastric emptying delays oral drug absorption
• Right: obesity-related infertility can reverse with weight loss
• Oversimplified: the birth control absorption effect varies by formulation and timing

What should you actually know?

If you are taking oral contraceptives and a GLP-1 medication like semaglutide or tirzepatide, talk to your prescriber about your contraceptive method. The FDA label for Ozempic specifically recommends using a non-oral contraceptive or adding a barrier method for four weeks after starting semaglutide and for four weeks after each dose increase. This is not a theoretical concern. It is on the label.

The fertility restoration angle deserves more clinical attention than it gets. Women with PCOS, hypothalamic dysfunction secondary to obesity, or anovulation related to metabolic dysfunction may see ovulatory cycles resume during significant weight loss. This can happen faster than expected. If pregnancy is not your goal, do not assume infertility is reliable contraception. If pregnancy is your goal, this is worth a conversation with your OB-GYN or reproductive endocrinologist before starting or stopping a GLP-1 medication.

One more thing: the FDA has not approved semaglutide or tirzepatide for use during pregnancy. Animal studies have shown fetal harm at certain exposures. Women who become pregnant while on these medications should contact their prescriber immediately.

Bottom line

The core warning in this video is worth hearing, even if the creator fumbles the pharmacology label. The "Ozempic babies" phenomenon is real enough that clinicians are actively discussing it. But the agonist versus antagonist error is the kind of mistake that erodes trust in an otherwise decent public health message. Verify with your provider, not your For You page.